
X
NHS England takes charge on market access
https://pharmaphorum.com/views-analysis-market-access/perjeta-benefits-nhs-england-takes-charge/
NICE suggests interim CDF funding while further data is gathered.
Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.
Lilly’s drug will be re-appraised in 2020